Toronto Dominion Bank’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Toronto Dominion Bank’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-31	Closed	-$3K	–	1931
2023 Q2	$3K	Buy	+31	New	+$2.93K	﹤0.01%	1357

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Toronto Dominion Bank's RETA Position: Q3 2023 in Review

Toronto Dominion Bank sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 31 shares — an estimated $3K sold.

Toronto Dominion Bank first reported a position in RETA in Q2 2023 and held it in 1 quarter. The position peaked at $3K in Q2 2023. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Toronto Dominion Bank reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Toronto Dominion Bank sold 31 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $3K.
Toronto Dominion Bank first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2023 and held it in 1 quarter.
Toronto Dominion Bank's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $3K in Q2 2023.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Toronto Dominion Bank's 13F filing for Q3 2023, filed 14 Nov 2023.